Potential Diagnostic Power of Blood Circular RNA Expression in Active Pulmonary Tuberculosis

Zhongqing Qian, Hui Liu, Musheng Li, Junchao Shi, Na Li, Yao Zhang, Xiaojie Zhang, Jingzhu Lv, Xueying Xie, Yunfei Bai, Qinyu Ge, Eun-A Ko, Haiyang Tang, Ting Wang, Xiaojing Wang, Zhaohua Wang, Tong Zhou, Wanjun Gu

Southeast University, 2 Sipailou, Nanjing, Jiangsu 210096, China.

Research Paper

Abstract

Background: Circular RNAs (circRNAs) are a class of novel RNAs with important biological functions, and aberrant expression of circRNAs has been implicated in human diseases. However, the feasibility of using blood circRNAs as disease biomarkers is largely unknown.

Methods: We explored the potential of using human peripheral blood mononuclear cell (PBMC) circRNAs as marker molecules to diagnose active pulmonary tuberculosis (TB).

Findings: First, we demonstrated that circRNAs are widely expressed in human PBMCs and that many are abundant enough to be detected. Second, we found that the magnitude of PBMC circRNAs in TB patients was higher than that in the paired healthy controls. Compared with host linear transcripts, the circRNAs within several pathways are disproportionately upregulated in active TB patients, including “Cytokine-cytokine receptor interaction”, “Chemokine signaling pathway”, “Neurotrophin signaling pathway”, and “Bacterial invasion of epithelial cells”. Based on the differentially expressed circRNAs within these pathways, we developed a PBMC circRNA-based molecular signature differentiating active TB patients from healthy controls. We validated the classification power of the PBMC circRNA signature in an independent cohort with the area under the receiver operating characteristic curve (AUC) at 0.946.

Interpretation: Our results suggest that PBMC circRNAs are potentially reliable marker molecules in TB diagnosis.

© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Circular RNAs (circRNAs) are a class of novel RNAs that are expressed across the eukaryotic tree of life (Jeck and Sharpless, 2014; Wang et al., 2014). circRNAs can be formed by back-splicing, which is a non-canonical process in RNA splicing (Jeck and Sharpless, 2014). Although little is known regarding the exact mechanisms of circRNA biogenesis, some factors have been shown to regulate this process, such as flank intronic sequences (Liang and Wilusz, 2014; Vicens and Westhof, 2014; Zhang et al., 2014) and RNA-binding proteins (Barrett et al., 2015; Qu et al., 2015). CircRNAs have been revealed to perform several important functions, including microRNA (miRNA) sponges (Hansen et al., 2013; Meneczak et al., 2013), alternative RNA splicing regulation (Conn et al., 2017), and transcriptional regulation of the parental gene (Li et al., 2015b). Recent studies have also suggested that some circRNAs can be translated in a cap-independent translation manner and function in myogenesis (Legnini et al., 2017; Pantaleo et al., 2017; Yang et al., 2017). Furthermore, circRNAs have been found to be differentially expressed across human tissues and cell types (Guo et al., 2014; Salzman et al., 2013) and extraordinarily enriched in the mammalian brain (Rybalka-Wolf et al., 2015; You et al., 2015). Although circRNAs are generally expressed at low levels (Chen, 2016; Guo et al., 2014), some circRNAs are expressed more abundantly than their linear counterparts (Salzman et al., 2013). Dynamic circRNA profiles are related to neurogenesis (Rybalka-Wolf et al., 2015), mouse brain development...
2.1. Human Subjects

This study was approved by the Ethics Committee of Bengbu Medical College, with written informed consent obtained from all subjects. This was conformed to standards indicated by the Declaration of Helsinki. The diagnosis of active pulmonary TB was based on established international guidelines (Lewinsohn et al., 2017). Subjects with other concurrent infectious diseases were excluded. All the subjects investigated were of Chinese Han descent. The discovery cohort included two subjects with active pulmonary TB and two age- and gender-matched healthy controls: one young male case-control pair and one senior female case-control pair (Supplementary Table S1). The validation cohort consisted of 10 TB patients and 11 healthy controls, with no significant difference in age and gender between the cases and controls (Supplementary Table S2). The TB patients in the discovery and validation cohorts were recruited from the First Hospital of Huainan City and the Infectious Disease Hospital of Bengbu City, respectively. The healthy controls were recruited from Bengbu Medical College. Several clinical TB status indicators of each individual in the validation cohort, including the number of cavities, diameter of the largest cavities, and sputum smear grade were obtained.

2.2. Cell Purification, RNA Isolation and circRNA Expression Profiling

PBMCs were collected from all subjects in the discovery and validation cohorts. To profile PBMC circRNA expression in the discovery cohort, we constructed ribosomal RNA (rRNA)-depleted RNA-seq libraries using PBMC total RNA from each person in the discovery cohort. The expression of PBMC circRNAs in the discovery cohort was also profiled using the CapitalBio Technology Human CircRNA Array v2 (CapitalBio Technology, Beijing, China). The experimental details of cell purification, RNA isolation, RNA-seq library preparation and sequencing, and circRNA microarray expression profiling were available in Supplementary Methods. Raw sequencing reads were available at the NCBI Short Read Archive (SRA) (Kodama et al., 2012) under the accession number SRP115429, and circRNA microarray data were deposited at the NCBI Gene Expression Omnibus (GEO) (Edgar et al., 2002) under the accession number GSE103188.

2.3. RNA-seq Data of Whole Blood and Other Blood Components

To compare the circRNA repertoire in PBMCs with that in whole blood and other blood components, we collected several RNA-seq datasets from public databases, which included six samples of human whole blood (Memiczak et al., 2015), three samples of human blood platelets (Kissopoulou et al., 2013), and one sample of human red blood cells (RBCs) (Alhasan et al., 2016) (Supplementary Table S3). All these samples were sequenced using rRNA-depleted RNA-seq libraries in their original studies (Alhasan et al., 2016; Kissopoulou et al., 2013; Memiczak et al., 2015). We downloaded the raw RNA-seq reads of these samples from SRA (Kodama et al., 2012).

2.4. Identification and Expression Quantification of circRNAs From RNA-seq Data

The raw RNA-seq reads were filtered by removing adaptor sequences, contamination, and low-quality reads. To assure the sequencing performance and library quality, we used RNA-SeQC (DeLuca et al., 2012) to assess the data quality of each RNA-seq dataset. For each sample, we identified all putative circRNAs using CIRI (Gao et al., 2015) with default parameter settings. After circRNA identification, we quantified the expression values of all identified circular transcripts and known linear transcripts in the Ensembl (Cunningham et al., 2015) human gene annotation (release 87) using our recent developed tool, Sailfish (Li et al., 2017), with default settings. For each host gene, the transcripts per million (TPM) values of both linear and circular transcripts were recorded. These circRNA identification and quantification procedures were performed for both our PBMC and the public (the other blood component) RNA-seq raw data. The normalized TPM values of circRNAs were used to explore the global differences of circRNA repertoire among human blood components.
2.5. Inferring Differentially Expressed Pathways and circRNAs

To discover PBMC circRNA signature in differentiating TB patients from healthy controls, we identified differentially expressed pathways and circRNAs from human PBMC RNA-seq and microarray data, respectively. First, we aggregated circRNAs into pathway-level mechanisms using KEGG annotations. A paired Wilcoxon signed-rank test was performed to compare the paired circRNA expression profiles restricted to a given KEGG pathway between paired control and TB samples (Gardeux et al., 2014). The pathways with an adjusted P-value < 0.05 after Benjamini and Hochberg correction were deemed differentially expressed. Next, the edgeR (Robinson et al., 2010) and SAM (Tusher et al., 2001) algorithms were used to identify the differentially expressed circRNAs. For the RNA-seq data, only the circRNAs with a reads-per-million value > 5 in at least two samples were included. We further excluded the circRNAs with average junction read counts < 5. For the microarray data, only the circRNAs without absent calls were retained. We limited our analysis to the circRNAs with unique circBase (Glazar et al., 2014) annotation and removed the circRNAs on chromosomes X and Y to avoid the potential confounding sex factor. The circRNAs with a false discovery rate (FDR) < 5% were deemed differentially expressed.

2.6. qRT-PCR Validation

We validated the performance of the dysregulated PBMC circRNAs in differentiating active pulmonary TB patients from healthy controls in an independent validation cohort. qRT-PCRs were performed to quantify the expression of the prioritized PBMC circRNAs. We designed divergent primers for the selected circRNAs using CircInteractome (Dudekula et al., 2016) (Supplementary Table S4). qRT-PCRs were performed on a QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific, Massachusetts, USA) using a SYBR Green Real Master Mix with Rox (Tiangen, Beijing, China). The housekeeping gene, β-actin, was used as an internal control. The comparative CT ($2^{-\Delta\Delta CT}$) method was used to obtain the fold change of circRNA expression levels, and Student's t-test was used to test its statistical significance.

2.7. CircRNA-based TB Index

We applied a scoring method used in our previous study to assign each human subject a TB index (Qian et al., 2016): $I = \sum_{i=1}^{n} (e_i - \mu_i) / \tau_i$. Here, $I$ is the circRNA-based TB index; $n$ is the number of circRNAs; $e_i$ denotes the expression level of circRNA $i$; and $\mu_i$ and $\tau_i$ are the mean and standard deviation of the expression of circRNA $i$ across all samples, respectively. A higher TB index implies a higher likelihood of active TB.

3. Results

3.1. Landscape of circRNA Expression in Human PBMCs

Previous studies have suggested that circRNAs are enriched in human peripheral whole blood (Menczak et al., 2015), platelets (Alhasan et al., 2016), and exosomes (Li et al., 2015a), and circRNAs in whole blood and blood components could be used as biomarker molecules. To explore whether PBMC circRNAs are potential molecular markers as well, we first investigated the landscape of expressed circular transcripts and their expression pattern in human PBMCs. We
 sequenced four rRNA-depleted RNA-seq libraries of human PBMC samples in the discovery cohort (Supplementary Table S3). The expression of both mRNAs and circRNAs was simultaneously quantified by Sailfish-cir (Li et al., 2017). In total, 5175 parental genes were found to express circular transcripts in these four human PBMC samples, among which the circular transcripts of 131 parental genes were highly expressed with an average TPM > 100.

We also analyzed the rRNA-depleted RNA-seq data of human whole blood, platelets, and RBCs (Supplementary Table S3). The PBMC circRNA repertoire was then compared with the circRNAs identified in whole blood, platelets, and RBCs. We observed that the number of parental genes with circular transcripts was comparable among PBMCs, platelets, and whole blood (Fig. 2a). There were 3739 host genes commonly expressing circular transcripts in PBMCs, platelets, and whole blood (Fig. 2a). The circRNA expression level in PBMCs was significantly higher than that in whole blood and RBCs (t-test: \( P < 10^{-10} \)) but lower than that in platelets (t-test: \( P < 10^{-15} \)) (Fig. 2b). In comparison, human RBCs had the least number of identified circRNAs (Fig. 2a) and the lowest level of circRNA expression (Fig. 2b). These results suggest that circRNAs are widely expressed in human PBMCs. Furthermore, the expression of a substantial number of circular transcripts was high enough to be detected, which ensures that circRNAs in PBMCs, like those in whole blood and platelets, meet the essential requirements as molecular markers.

3.2. Pathway-based Analysis of PBMC circRNA Dysregulation in TB Using RNA-seq

Next, we investigated the difference in PBMC circRNA expression between TB patients and healthy controls in the discovery cohort. We observed that the RNA-seq reads fraction of circRNA transcripts in the PBMC transcriptome was consistently increased in both young and senior TB patients compared with healthy controls (Fig. 2c). The circRNA TPM of the TB patients was significantly higher than that of the healthy controls (Kolmogorov-Smirnov test: \( P < 10^{-10} \)) (Fig. 2d).

Given the broad differences in PBMC circRNA expression between TB patients and healthy controls, we performed a pathway-based paired-sample analysis to identify the dysregulated biological processes by pooling circRNAs into host gene pathways. In this analysis, we assumed that the function of a given circRNA could be associated with the known
function of its parental gene, as circRNAs can potentially cis-regulate their corresponding host genes (Chen, 2016; Li et al., 2015b; Veno et al., 2015). Briefly, a paired Wilcoxon signed-rank test was applied to compare the paired circRNA expression profiles restricted to a given KEGG pathway between healthy controls and TB patients for the young and senior pairs, respectively (Gardeux et al., 2014). Unlike conventional transcriptomic approaches that have been developed to uncover molecular signatures across a large population of human subjects, this approach enables discovery of dysregulated pathways unique to individual case-control pairs and highlights both the individuality and commonality of a clinical trait (Gardeux et al., 2014).

In total, five KEGG pathways were found to be commonly upregulated (adjusted \( P < 0.05 \)) regarding circRNA expression in both young and senior TB patients (Fig. 3a), including “Cytokine-cytokine receptor interaction,” “Chemokine signaling pathway,” “Fc gamma R-mediated phagocytosis,” “Neurotrophin signaling pathway,” and “Bacterial invasion of epithelial cells” (Fig. 3b and Supplementary Table S5). The Z-score of the Wilcoxon test was significantly and positively correlated between the young and senior TB control pairs (Spearman’s rank correlation test: \( \rho = 0.506 \) and \( P < 10^{-10} \)) (Fig. 3a), which reflects the commonality in circRNA dysregulation patterns between young and senior TB patients.

To understand whether the alteration of circRNA abundance in the five prioritized pathways is simply a function of the host gene dysregulation, we computed the fraction of circRNA reads over the total read count (reads from both circular and linear transcripts) for each host gene. We found that the fraction of circRNA reads was significantly higher in TB patients than in healthy controls in all five pathways (paired Wilcoxon test: \( P < 0.05 \)) (Fig. 3c), which suggests that circRNA expression is somewhat independent of host linear transcripts and, at least to a certain extent, the circRNA dysregulation in TB PBMCs is not a secondary consequence of the host gene expression.

### 3.3. Technical Validation of the Prioritized Pathways Using a circRNA Microarray

To verify that the above findings were not caused by potential technical bias introduced by RNA-seq procedures (Lahens et al., 2014; Zheng et al., 2011), we further performed circRNA microarray analysis of the same PBMC RNA samples treated by RNase R (Jeck et al., 2013). The CapitalBio Technology Human CircRNA Array v2 (\( 4 \times 180K \)) was used to quantify circRNA expression. As indicated in Fig. 4, the microarray data perfectly mirrored our findings from the RNA-seq analysis. The five prioritized pathways were consistently upregulated with respect to circRNA expression (paired Wilcoxon test: \( P < 0.05 \)) (Fig. 4). These results confirmed that the dysregulated pathways we prioritized from TB PBMC circRNAs were independent of the circRNA detection and quantification methods.

### 3.4. Classification Power of PBMC circRNA Expression in TB

Finally, we explored the predictive power of PBMC circRNA expression in differentiating TB patients from a healthy population. We further explored the RNA-seq and microarray data to compare the expression of individual circRNAs within the five prioritized pathways between TB patients and healthy controls. In total, seven circRNAs with unique circBase annotations were identified to be commonly upregulated in TB PBMCs in both the RNA-seq and microarray data (see Methods for details), which was designated the 7-circRNA signature (Table 1 and Fig. 5a).

The 7-circRNA signature was then assessed in the validation cohort with 11 healthy controls and 10 TB patients. qRT-PCR was used to quantify the expression of each individual circRNA. Elevated expression was observed for all the prioritized circRNAs (t-test: \( P < 0.05 \)), except for hsa_circ_0000414 (t-test: \( P = 0.171 \)) (Fig. 5b). Principal component analysis indicated that the 7-circRNA signature differentiated TB...
patients from healthy controls in the validation cohorts (Fig. 5c). To systematically evaluate the classification power of the 7-circRNA signature, a circRNA-based TB index was assigned to each subject (see Methods for details). The TB index is a linear combination of the 7-circRNA expression values, and a higher TB index implies a higher likelihood of TB. We found that the 7-circRNA-based TB index was significantly higher in TB patients than in healthy controls (\( P = 0.001 \)) (Fig. 5d). The area under the receiver operating characteristic (ROC) curve (AUC) was 0.946 (Fig. 5e). We further tested whether the predictive power of the circRNA-based TB index was dependent on standard TB clinical indicators, including number of cavities, diameter of the largest cavities, and sputum smear grade. Multivariate logistic regression indicated that the 7-circRNA-based TB index was the most significant predictor of TB status (\( P = 0.038 \)) (Supplementary Table S6). This suggests that circRNA expression information adds independent value to TB diagnosis. We also investigated the correlation between the 7-circRNA-based TB index and the above clinical indicators. However, no significant correlation was observed (Supplementary Table S7), which may be partly due to the limited sample size in the validation cohort.

4. Discussion

In this study, we explored the potential of using human PBMC circRNAs as the molecular markers to diagnose active pulmonary TB. Due to the remarkable stability of circRNAs (Enuka et al., 2016), several groups have already investigated circRNA expression in easily accessible human body fluids to determine the potential of circRNAs as biomarkers (Alhasan et al., 2016; Bahn et al., 2015; Li et al., 2015a; Memczak et al., 2015). For example, Memczak et al. reported the detection of thousands of circRNAs and high expression of hundreds of circRNAs in human peripheral whole blood (Memczak et al., 2015). Some comprehensive analysis further revealed stable and enriched circRNAs in some human blood components, including erythrocytes (Alhasan et al., 2016), platelets (Alhasan et al., 2016), and exosomes (Li et al., 2015a). As an alternative to using human peripheral blood, Bahn et al. identified >400 circRNAs in cell-free saliva samples (Bahn et al., 2015). Unlike the above studies, we investigated the circRNA repertoire in a different blood component, human PBMCs. PBMCs contain any peripheral blood cell with a round nucleus, including monocytes and lymphocytes. In our results, we showed wide and abundant circRNA expression in human PBMCs, which is comparable to the circRNA landscapes in human whole blood, RBCs, and platelets (Fig. 2A and B). This result complements previous observations by Alhasan et al. (2016), who found that circular transcripts are enriched in human platelets, with a 17- to 188-fold change relative to nucleated tissues, which is a common signature of anucleate cells (Alhasan et al., 2016). Our study suggests that, similar to anucleate cells, the magnitude of PMBC circRNA expression may also be higher than that of nucleated tissues and other nucleate cells. This is potentially an exciting feature of human PBMCs, as it implies that circRNAs in human PBMCs may be used as liquid biomarker molecules for human diseases.

Compared with previous blood circRNA studies (Alhasan et al., 2016; Li et al., 2015a; Memczak et al., 2015), we pushed several steps forward in investigating the potential of using blood circRNAs as diagnostic markers of human diseases. In addition to the exploration of the circRNA repertoire in human PBMCs, we investigated several key questions in biomarker development, including the differential expression of circRNAs between cases and controls and the development and validation of a circRNA signature. We showed that the magnitude of PBMC circRNAs in TB patients was significantly higher than that of the paired healthy controls (Fig. 2C and D). A KEGG pathway-based paired-sample analysis identified several dysregulated biological processes in human PBMCs, including “Cytokine-cytokine receptor interaction,” “Chemokine signaling pathway,” “Fc gamma R-mediated phagocytosis,” “Neurotrophin signaling pathway,” and “Bacterial invasion of epithelial cells” (Fig. 3b and Supplementary Table S5). Most of these dysregulated pathways are relevant to the occurrence and development of TB. For example, cytokines, chemokines, and their receptors are critical factors in achieving an optimal balance between innate and adaptive immune cells, which can determine the progression or outcome of Mycobacterium tuberculosis infection (Dorhoi and Kaufmann, 2016; Monin and Khader, 2014), while Fc gamma R may play a role in Fc-mediated Ab effector functions in pathogen clearance (Lu et al., 2016). Based on these dysregulated pathways, we prioritized seven differentially expressed PBMC circRNAs in TB patients (Fig. 5a), yielding a 7-circRNA TB molecular signature. We further validated the predictive power of the 7-

![Table 1](image)

| circBase ID | Genomic position | Strand | Length | Gene | Associated KEGG pathway |
|-------------|------------------|--------|--------|------|--------------------------|
| hsa_circ_0000414 | chr12:66597490-66605377 | + | 455 | IRAK3 | Neurotrophin signaling pathway |
| hsa_circ_0000681 | chr16:23999828-24046868 | + | 324 | PRKC8 | Chemokine signaling pathway; Fc gamma R-mediated phagocytosis |
| hsa_circ_0002113 | chr21:34793786-34805178 | + | 673 | IFNCR2 | Cytokine-cytokine receptor interaction |
| hsa_circ_0002362 | chr9:458652-9468040 | + | 341 | ASAP2 | Fc gamma R-mediated phagocytosis |
| hsa_circ_0002908 | chr8:141840570-141874498 | − | 286 | LTB | Chemokine signaling pathway; Bacterial invasion of epithelial cells |
| hsa_circ_0007297 | chr3:119582265-119624699 | + | 420 | G3EB | Chemokine signaling pathway; Neurotrophin signaling pathway |
| hsa_circ_0063179 | chr22:37328806-37330036 | + | 303 | CSF2RB | Cytokine-cytokine receptor interaction |

![Fig. 4](image)

Fig. 4. Technical validation of the five prioritized KEGG pathways using a circRNA expression microarray. Total RNA was treated with RNase R to remove linear transcripts and then subject to microarray hybridization.

![Fig. 5](image)

Fig. 5. (A) PBMC circRNA expression levels in young and senior individuals. (B) PBMC circRNA expression levels in TB patients and healthy controls. (C) 7-circRNA TB index was assigned to each subject. (D) ROC curve of the 7-circRNA TB index in healthy controls and TB patients. (E) Area under the ROC curve (AUC) of the 7-circRNA TB index. (F) The 7-circRNA TB index was significantly higher in TB patients than in healthy controls.

![Fig. 6](image)

Fig. 6. The 7-circRNA signature.
circRNA signature to differentiate TB patients from healthy controls in an independent cohort (Fig. 5b). Our results strongly suggest that PBMC circRNAs are promising biomarkers to differentiate active TB patients from healthy controls (Fig. 5c–e). However, more thorough studies are needed to test the performance of our 7-circRNA signature as a TB diagnostic biomarker. Due to the limited sample size of the discovery cohort, we used a pathway-based algorithm to control false discovery rate of the prioritized circRNAs. This method potentially overlooks the circRNAs without pathway annotation. In future study, unbiased screening of circRNAs at the whole transcriptomic level in a large cohort will be highly helpful. Moreover, some other diseases with similar clinical phenotypes, such as lung cancers, pneumonias, and pulmonary

**Fig. 5.** The 7-circRNA signature. (a) Expression heatmap of the circRNAs within the 7-circRNA signature in the discovery cohort. The expression measured by both RNA-seq and circRNA microarray is displayed. (b) Comparison of the expression levels of the 7-circRNA signature between the healthy controls and TB patients in the validation cohort. The error bars represent the standard error of the mean. (c) Principal component analysis of the 7-circRNA signature. PC1: the first principal component; PC2: the second principal component. (d) Comparison of the circRNA-based TB index between the healthy controls and TB patients in the validation cohort. (e) The ROC curve of the TB index in distinguishing TB patients from healthy controls. The light blue area indicates the confidence interval of the ROC curve.
Appendix A: Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2017.12.007.

References

Abboish, C., Birkbak, NJ., Wilson, G.A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D.A., Veeriah, S., Rosenthal, R., et al., 2017. Phylogenetic eCTDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446–451.
Alhasan, AA., Izougu, O.G., Al-Baloq, H.H., Steyn, J.S., Evans, A., Colanzi, M., Chevaert, A., Mountford, J.C., Marenoth, L., Elliott, D.J., et al., 2016. Circular RNA enrichment in platelet concentrate in a signature of transcriptome degradation. Blood 127, e1–e11.
Bahn, J.H., Zhang, Q., Li, F., Chan, T.M., Lin, X., Kim, Y., Wong, D.T., Xiao, X., 2015. The landscape of microRNA, Piwi-interacting RNA, and circular RNA in human saliva. Clin. Chem. 61, 221–230.
Barrett, S.P., Wang, P.L., Salzman, J., 2015. Circular RNA biogenesis can proceed through an exon-containing lariat precursor. eLife 4, e07540.
Bloom, C.L., Graham, C.M., Berry, M.P., Rozekas, F., Redford, P.S., Wang, X., Xu, Z., Wilkinson, K.A., Wilkinson, R.J., Kendrick, V., et al., 2013. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One 8, e70630.
Bonizzato, A., Gaffo, E., de Kronie, G., Bortolussi, S., 2016. Circular RNAs in hematopoiesis and hematological malignancies. Blood Cancer J. 6, e483.
Byron, S.A., Keuren-Jensen, K.R., Engelhard, D.M., Carpentier, J.D., Craig, D.W., 2016. Translating RNA sequencing into clinical diagnostics: opportunities and challenges. Nat. Rev. Genet. 17, 257–271.
Chen, L.-L., 2016. The biogenesis and emerging roles of circular RNAs. Nat. Rev. Mol. Cell Biol. 17, 205–211.
Conn, S.J., Pillman, K.A., Toubia, J., Conn, V.M., Salmandini, M., Phillips, C.A., Roslan, S., Schreiber, A.W., Gregory, P.A., Goodall, G.J., 2015. The RNA binding protein quaking regulates formation of circRNAs. Cell 160, 1125–1134.
Conn, Y.M., Hugouvieux, V., Nayak, A., Conos, S.A., Capovilla, G., Cildir, G., Jourdian, A., Tergaonkar, V., Schmid, M., Zubieta, C., et al., 2017. A circRNA from SEPALATA3 regulates splicing of its cognate mRNA through R-loop formation. Nat. Plants 3, 17053.
Cunningham, F., Amode, M.R., Barrell, D., Beal, K., Billis, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fitzgerald, S., et al., 2015. Ensembl 2015. Nucleic Acids Res. 43, D662–D669.
Deluca, D.S., Levin, J.Z., Siwachenko, A., Fennell, T., Nazaire, M.D., Williams, C., Reich, M., Winckler, W., Getz, G., 2012. RNA-seqQC: RNA-seq metrics for quality control and analysis. Bioinformatics. 28, 1530–1532.
Dorhoi, A., Kaufmann, S.H., 2016. Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis. Semin. Immunopathol. 38, 153–166.
Dudekula, D.R., Panda, A.C., Grummatikakis, I., De, S., Abdelmohsen, K., Gorospe, M., 2016. CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol. 13, 34–42.
Dvinge, H., Rice, R.E., Ilagan, J.D., Stieweall, D.L., Moshinski, S., Bradley, R.K., 2014. Sample processing obscures cancer-specific alterations in leukemic transcriptomes. Proc. Natl. Acad. Sci. U. S. A. 111, 16802–16807.
Edgar, R., Domrachev, M., Lash, A.E., 2002. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30, 207–210.
Enuka, Y., Lauriola, M., Feldman, M.E., Sas-Chen, A., Ulitsky, I., Yarden, Y., 2016. Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Res. 44, 1370–1383.
Gao, Y., Wang, J., Zhao, F., 2015. CBIR: an efficient and unbiased algorithm for de novo circular RNA identification. Genome Biol. 16, 4.
Gardeux, V., Achour, I., Li, J., Mainsenclin-Cine, M., Li, H., Pesce, L., Pariandin, G., Bahroos, N., Wiin, K., Foster, L., et al., 2014. ’On-of-pathways’ unredits personal deregulated mechanisms from a single pair of RNA-Seq samples: towards precision medicine. J. Am. Med. Inform. Assoc. 21, 1015–1025.
Glazar, P., Papavasileiou, P., Rajewsky, N., 2014. circBase: a database for circular RNAs. RNA 20, 1665–1670.
Guo, J.J., Agarwal, V. Guo, H., Barrell, D.P., 2014. Expanded identification and characterization of mammalian circular RNAs. Genome Biol. 15, 409.
Hansen, T.B., Jensen, T.J., Clausen, B.H., Bramsen, JB., Finsem, B., Damgaard, C.K., Jensen, J., 2013. Natural RNA circles function as efficient microRNA sponges. Nature 495, 384–388.
Jasenosky, L.D., Scriba, T.J., Hanekom, W.A., Goldfeld, A.E., 2015. T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunol. Rev. 264, 74–87.
Jekc, W.R., Sharpless, N.E., 2014. Detecting and characterizing circular RNAs. Nat. Biotechnol. 32, 453–461.
Jekc, W.R., Sorrentino, J.A., Wang, K., Slevin, M.K., Burd, C.E., Liu, J., Marzluff, W.F., Sharpless, N.E., 2013. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA 19, 141–153.
Kodama, Y., Shumway, M., Leinonen, R., International Nucleotide Sequence Database, C., 2012. The sequence read archive: explosive growth of sequencing data. Nucleic Acids Res. 40, D54–56.
Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., Maier, L., Mackowiak, A., Bahler, J., Rajewsky, N., 2015. Identification and characterization of circular RNAs as a new class of putative biomarkers in human blood. PLoS One 9, e95116.

Meng, S., Zhou, J., Zheng, X., Xu, Z., Zang, Y., Li, P., Wu, M., 2017. CircRNA: functions and properties of a novel potential biomarker for cancer. Mol. Cancer 16, 94.

Min, J.L., Barrett, A., Watts, T., Pettersson, F.H., Lockstone, H.E., Lindgren, C.M., Taylor, J.M., Allen, M., Zonderván, K.T., McCarthy, M.L., 2010. Variability of gene expression profiles in human blood and lymphoblastoid cell lines. BMC Genomics 11, 984.

Monin, L., Khader, S.A., 2014. Chemokines in tuberculosis: the good, the bad and the ugly. Semin. Immunol. 26, 552–558.

Pai, M., Behr, M.A., Dowdy, D., Dhelda, K., Divangahi, M., Boehme, C.C., Gän斯berg, A., Swaniniathan, S., Spigelman, M., Getahun, H., et al., 2016. Tuberculosis. Nat. Rev. Dis. Primers 2, 16076.

Pamudurti, N.R., Bartok, O., Jens, M., Ashwal-Fluss, R., Stottmeister, C., Ruhe, L., Hanan, M., Wyler, E., Perez-Hernandez, D., Rambberger, E., et al., 2017. Translation of CircRNA. Mol. Cell 66, 9–21.

Qian, Z., Lv, J., Kelly, G.T., Wang, H., Zhang, X., Gu, W., Yin, X., Wang, X., Zhou, T., 2016. Expression of nuclear factor, erythroid 2-like 2-mediated genes differentiates tuberculosis. Tuberculosis (Edinburgh, Scotland) 99, 56–62.

Qu, S., Yang, X., Li, X., Wang, J., Gao, Y., Shang, R., Sun, W., Dou, K., Li, H., Circular, R.N.A., 2015. A new star of noncoding RNAs: Cancer Lett. 365, 141–148.

Robinson, M.D., McCarthy, D.J., Smyth, G.K., 2010. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140.

Roe, J.K., Thomas, N., Gil, E., Best, K., Tsai, E., Morris-Jones, S., Stafford, S., Simpson, N., Witt, K.D., Chain, B., et al., 2016. Blood transcriptomic diagnosis of pulmonary and extrapulmonary tuberculosis: JCI Insight 1, e87238.

Rybak-Wolf, A., Stottmeister, C., Gázár, P., Jens, M., Pino, N., Giusti, S., Hanan, M., Behm, M., Bartok, O., Ashwal-Fluss, R., et al., 2015. Circular RNAs in the mammalian brain are highly abundant, conserved, and dynamically expressed. Mol. Cell 58, 1–16.

Salzman, J., Chen, R.E., Olsen, M.N., Wang, P.L., Brown, P.O., 2013. Cell-type specific features of circular RNA expression. PLoS Genet. 9.

Sweeney, T.E., Braviak, L., Tato, C.M., Khati, P., 2016. Genome-wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis. Lancet Respir. Med. 4, 213–224.

Tusher, V.G., Tibshirani, R., Chu, G., 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U. S. A. 98, 5116–5121.

Veno, M.T., Hansen, T.B., Venø, S.T., Claussen, B.H., Grebing, M., Finsen, B., Holm, I.E., Kjems, J., 2015. Spatio-temporal regulation of circular RNA expression during porcine embryonic brain development. Genome Biol. 16, 245.

Vicens, Q., Westhof, E., 2014. Biogenesis of circular RNAs: Cell 159, 13–14.

Wang, P.L., Bao, Y., Yee, M.–C., Barrett, S.P., Hogan, G.J., Olsen, M.N., Dinneny, J.R., Brown, P.O., Salzman, J., Circular, R.N.A. Is, 2014. Expressed across the eukaryotic tree of life. PLoS One 9, e95116.

World Health Organization, 2016. Global T tuberculosis Report 2016. WHO, 2016.

Yang, W., Sun, M., Song, X., Wu, P., Zhang, Y., Jin, Y., Yang, Y., Chen, L., Wang, Y., et al., 2017. Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Res. 27, 626–641.

You, X., Vlatković, I., Babic, A., Will, T., Epstein, I., Tushiev, G., Akbalik, G., Wang, M., Gloc, C., Quedena, C., et al., 2015. Neural circular RNAs are derived from synaptic genes and regulated by development and plasticity. Nat. Neurosci. 18, 603–610.

Zak, D.E., Penn-Nicholson, A., Scriba, T.J., Thompson, E., Suliman, S., Aron, L.M., Mahomed, H., Erasmus, M., Whatmey, W., Hussey, G.D., et al., 2016. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 387, 2312–2322.

Zhang, X.–O., Wang, H.–B., Zhang, Y., Lu, X., Chen, L.–Y., Yang, L., 2014. Complementary sequence-mediated exon circularization. Cell 159, 134–147.

Zhao, Z., Li, X., Gao, C., Jian, D., Hao, P., Rao, L., Li, M., 2017. Peripheral blood circular RNA hsa_circ_0124644 can be used as a diagnostic biomarker of coronary artery disease. Sci. Rep. 7, 39918.

Zheng, W., Chung, L.M., Zhao, H., 2011. Bias detection and correction in RNA-sequencing data. BMC Bioinform. 12, 290.